Results 221 to 230 of about 31,126 (279)

Tocilizumab provides a potential therapeutic option for the management of hyperhaemolysis syndrome in sickle cell disease: A case series and brief narrative overview of the literature

open access: yesTransfusion Medicine, Volume 36, Issue 1, Page 66-71, February 2026.
Abstract Background and Objectives Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases.
S. Wolf   +8 more
wiley   +1 more source

Divergence in DNACPR and resuscitation policies: institutional survey in England. [PDF]

open access: yesBMJ Support Palliat Care
Fitton E   +5 more
europepmc   +1 more source

Synergetic hemostatic potential of fibrinogen γ‐chain peptide‐coated, adenosine 5′‐diphosphate‐encapsulated liposomes combined with whole blood transfusion: A preclinical study

open access: yesTransfusion, Volume 66, Issue 2, Page 405-412, February 2026.
Abstract Background Whole blood (WB) transfusions are being reevaluated because of their high hemostatic capacity and reduced volume. Fibrinogen γ‐chain peptide‐coated, adenosine 5′‐diphosphate (ADP)‐encapsulated liposomes are potent hemostatic adjuvants promoting platelet thrombi formation.
Osamu Ishida   +6 more
wiley   +1 more source

End-of-life care in hospitalized patients with dementia. [PDF]

open access: yesJ Gerontol A Biol Sci Med Sci
Ong XW   +3 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy